๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Adjuvant trastuzumab for HER2-positive breast cancer

โœ Scribed by James Spicer; Mark Harries; Paul Ellis

Book ID
117290031
Publisher
The Lancet
Year
2005
Tongue
English
Weight
47 KB
Volume
366
Category
Article
ISSN
0140-6736

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Cost-effectiveness analysis of trastuzum
Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2-positive breast cancer
โœ Louis P. Garrison Jr; Deborah Lubeck; Deepa Lalla; Virginia Paton; Amylou Dueck; ๐Ÿ“‚ Article ๐Ÿ“… 2007 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 209 KB ๐Ÿ‘ 2 views

## Abstract ## BACKGROUND. Adding trastuzumab to adjuvant chemotherapy provides significant clinical benefit in patients with human epidermal growth factor receptor 2 (HER2)โ€positive breast cancer. A costโ€effectiveness analysis was performed to assess clinical and economic implications of adding t